Matches in SemOpenAlex for { <https://semopenalex.org/work/W2414406951> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2414406951 endingPage "71" @default.
- W2414406951 startingPage "767" @default.
- W2414406951 abstract "A clinical trial of Docetaxel was performed by tri-weekly administration in patients with advanced or recurrent breast cancer. However, careful observation is necessary for outpatients because serious neutropenia often occurs during the therapy. A bi-weekly schedule is recommended since weekly administration requires more visits to the hospital. Docetaxel is proved to express synergistic efficacy in combination with 5'-DFUR by induced dThdPase in vivo. But there are no clinical trials to evaluate efficacy of bi-weekly Docetaxel and 5'-DFUR combination therapy.To evaluate safety, the recommended dose of Docetaxel and the efficacy of biweekly Docetaxel and 5'-DFUR combination therapy.Patients with advanced or recurrent breast cancer within 1 regimen of prior chemotherapy and without prior use of both Docetaxel and 5'-DFUR were enrolled. 5'-DFUR was orally administered by 600 mg/day. Docetaxel was intravenously given for at least 2 cycles (8 weeks) by 30 mg/m(2) for level 1, 40 mg/m(2) for level 2 and 50 mg/m(2) for level 3. At each level with 3 cases enrolled,the maximum tolerated dose (MTD) level was defined as that in which 2 or 3 cases showed dose limiting toxicity (DLT). The recommended dose was defined as the dose before MTD level. Therapeutic safety was evaluated by analyses of adverse events with the recommended dose.MTD was in level 3 and the recommended dose of Docetaxel was 40 mg/m(2) of level 2. No DLT was observed in level 2, and this combination therapy seemed safe and feasible for outpatients. In addition, all 6 cases for whom therapeutic efficacy was evaluated expressed a clinical response." @default.
- W2414406951 created "2016-06-24" @default.
- W2414406951 creator A5000204553 @default.
- W2414406951 creator A5017936609 @default.
- W2414406951 creator A5037189408 @default.
- W2414406951 creator A5057315592 @default.
- W2414406951 creator A5069396542 @default.
- W2414406951 creator A5071839885 @default.
- W2414406951 creator A5075754635 @default.
- W2414406951 creator A5076042448 @default.
- W2414406951 creator A5084242343 @default.
- W2414406951 creator A5085258127 @default.
- W2414406951 date "2006-06-01" @default.
- W2414406951 modified "2023-09-26" @default.
- W2414406951 title "[Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]." @default.
- W2414406951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16770094" @default.
- W2414406951 hasPublicationYear "2006" @default.
- W2414406951 type Work @default.
- W2414406951 sameAs 2414406951 @default.
- W2414406951 citedByCount "0" @default.
- W2414406951 crossrefType "journal-article" @default.
- W2414406951 hasAuthorship W2414406951A5000204553 @default.
- W2414406951 hasAuthorship W2414406951A5017936609 @default.
- W2414406951 hasAuthorship W2414406951A5037189408 @default.
- W2414406951 hasAuthorship W2414406951A5057315592 @default.
- W2414406951 hasAuthorship W2414406951A5069396542 @default.
- W2414406951 hasAuthorship W2414406951A5071839885 @default.
- W2414406951 hasAuthorship W2414406951A5075754635 @default.
- W2414406951 hasAuthorship W2414406951A5076042448 @default.
- W2414406951 hasAuthorship W2414406951A5084242343 @default.
- W2414406951 hasAuthorship W2414406951A5085258127 @default.
- W2414406951 hasConcept C121608353 @default.
- W2414406951 hasConcept C126322002 @default.
- W2414406951 hasConcept C143998085 @default.
- W2414406951 hasConcept C197934379 @default.
- W2414406951 hasConcept C2776694085 @default.
- W2414406951 hasConcept C2776999253 @default.
- W2414406951 hasConcept C2777063308 @default.
- W2414406951 hasConcept C2781190966 @default.
- W2414406951 hasConcept C2781413609 @default.
- W2414406951 hasConcept C530470458 @default.
- W2414406951 hasConcept C535046627 @default.
- W2414406951 hasConcept C71924100 @default.
- W2414406951 hasConceptScore W2414406951C121608353 @default.
- W2414406951 hasConceptScore W2414406951C126322002 @default.
- W2414406951 hasConceptScore W2414406951C143998085 @default.
- W2414406951 hasConceptScore W2414406951C197934379 @default.
- W2414406951 hasConceptScore W2414406951C2776694085 @default.
- W2414406951 hasConceptScore W2414406951C2776999253 @default.
- W2414406951 hasConceptScore W2414406951C2777063308 @default.
- W2414406951 hasConceptScore W2414406951C2781190966 @default.
- W2414406951 hasConceptScore W2414406951C2781413609 @default.
- W2414406951 hasConceptScore W2414406951C530470458 @default.
- W2414406951 hasConceptScore W2414406951C535046627 @default.
- W2414406951 hasConceptScore W2414406951C71924100 @default.
- W2414406951 hasIssue "6" @default.
- W2414406951 hasLocation W24144069511 @default.
- W2414406951 hasOpenAccess W2414406951 @default.
- W2414406951 hasPrimaryLocation W24144069511 @default.
- W2414406951 hasRelatedWork W181704052 @default.
- W2414406951 hasRelatedWork W2080820783 @default.
- W2414406951 hasRelatedWork W2322401193 @default.
- W2414406951 hasRelatedWork W2383532643 @default.
- W2414406951 hasRelatedWork W2388730008 @default.
- W2414406951 hasRelatedWork W2606994187 @default.
- W2414406951 hasRelatedWork W2999789808 @default.
- W2414406951 hasRelatedWork W3000675521 @default.
- W2414406951 hasRelatedWork W3032029751 @default.
- W2414406951 hasRelatedWork W2184069695 @default.
- W2414406951 hasVolume "33" @default.
- W2414406951 isParatext "false" @default.
- W2414406951 isRetracted "false" @default.
- W2414406951 magId "2414406951" @default.
- W2414406951 workType "article" @default.